Business
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets. The Company remains fully committed to its co
About this update from Polyrizon Ltd.
[{"type":"text","content":"Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline ","length":102,"tagName":"p"},{"type":"text","content":"Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets.","length":352,"tagName":"p"},{"type":"text","content":"The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products such as PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery.","length":317,"tagName":"p"},{"type":"text","content":"In parallel, leveraging the Company’s strong cash position, the Board has authorized the exploration of investments in assets that are expected to generate revenues and create additional value for shareholders. This strategic initiative aims to efficiently utilize the Company’s resources to accelerate growth and deliver long-term shareholder value, while maintaining full focus on the primary medical pipeline.","length":412,"tagName":"p"},{"type":"text","content":"The Company will provide updates on any material developments as they occur.","length":76,"tagName":"p"},{"type":"text","content":"About Polyrizon","length":15,"tagName":"p"},{"type":"text","content":"Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged rete...